Harvard Bioscience, Inc. (HBIO) Stock Score, Valuation & Financial Research
Harvard Bioscience, Inc. is in the Healthcare sector and Medical - Instruments & Supplies industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 20/100.
Quick answer for HBIO
Harvard Bioscience, Inc. currently has a Wall Street Score of 20/100. The stored market price is $7.97. Its financial score is 12/100. Its valuation score is 0/100. The latest WSS change is -0.2 points. These figures are a research snapshot, not a buy or sell recommendation.
What Harvard Bioscience, Inc. does
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and
HBIO financial snapshot
- Wall Street Score:
- 20/100
- Current price:
- $7.97
- Market capitalization:
- $35.9M
- Revenue:
- $87.8M
- Net income:
- $-10.4M
- Free cash flow:
- $5.6M
- Cash:
- $6.5M
- Total debt:
- $44.2M
- EPS:
- -12.80
- Financial score:
- 12/100
- Valuation score:
- 0/100
- Revenue score:
- 22/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $5.6M, showing positive cash generation.
- The balance sheet shows $6.5M of cash versus $44.2M of total debt, so leverage deserves attention.
- The latest Wall Street Score change is -0.2 points: HBIO decreased 0.2 points because Asset declined by 2.4 points.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 12/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-08-14.
How to research HBIO
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.